F cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention byF cyclooxygenase-2 in human pancreatic

F cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by
F cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cycloxgenase inhibitors. Cancer 2001, 91:333?38. 25. Aoki T, Nagakawa Y, Tsuchida A, et al: Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumours. Oncol Rep 2002, 9:761?65. 26. Okami J, Yamamoto H, Fujiwara Y, et al: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999, 5:2018?024. 27. Giroux V, Malicet C, Barthet M, et al: p8 Is a NewTarget of Gemcitabine in Pancreatic Cancer Cells. Clin Cancer Res 2006, 235:235?41. 28. Akada M, Crnogorac-Jurcevic T, Lattimore S, et al: Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 2005, 11:3094?101. 29. Okami J, Simeone DM, Logsdon CD: Silencing of the Hypoxia-Inducible Cell Death Protein BNIP3 in pancreatic cancer. Cancer Res 2004, 64:5338?346.doi:10.1186/1479-5876-10-161 Cite this article as: Rathos et al.: Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclindependent kinase inhibitor, P276-00 in pancreatic cancers. Journal of Translational LY-2523355 site Medicine 2012 10:161.Submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer review ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submit
Liu et al. Journal of Translational Medicine 2013, 11:140 http://www.translational-medicine.com/content/11/1/RESEARCHOpen AccessProtein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasisLi-na PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/27597769 Liu1, Pei-yu Huang3, Zhi-rui Lin2, Li-juan Hu4, Jian-zhong Liang5, Man-zhi Li2, Lin-quan Tang3, Mu-sheng Zeng2, Qian Zhong2* and Bo-hang Zeng1*AbstractBackground: The aim of this study was to analyze the expression of protein tyrosine kinase 6 (PTK6) in nasopharyngeal carcinoma (NPC) samples, and to identify whether PTK6 can serve as a biomarker for the diagnosis and prognosis of NPC. Methods: We used quantitative RT-PCR and Western blotting analysis to detect mRNA and protein expression of PTK6 in NPC cell lines and immortalized nasopharyngeal epithelial cell lines. 31 NPC and 16 non-tumorous nasopharyngeal mucosa biopsies were collected to detect the difference in the expression of mRNA level of PTK6 by quantitative RT-PCR. We also collected 178 NPC and 10 normal nasopharyngeal epithelial cases with clinical follow-up data to investigate the expression of PTK6 by immunohistochemistry staining (IHC). PTK6 overexpression on cell growth and colony formation ability were measured by the method of cell proliferation assay and colony formation assay. Results: The expression of PTK6 was higher in most of NPC cell lines at both mRNA and protein levels than in immortalized nasopharyngeal epithelial cell lines (NPECs) induced by Bmi-1 (Bmi-1/NPEC1, and Bmi-1/NPEC2). The mRNA level of PTK6 was high in NPC biopsies compared to non-tumorous nasopharyngeal mucosa biopsies. IHC results showed the expression of PTK6 was significantly correlated to tumor size (P<0.001), clinical stage (P<0.001), and metastasis (P=0.016). The patients with high-expression of PTK6 had a significantly poor prognosis compared to those of low-expression (47.8 versus 80.0 , P<0.001), especially in the patients a.